Loading...

Media is loading
 

Date of Award

Spring 2021

Degree Name

Master of Medical Science (Physician Assistant)

Department

Physician Assistant; College of Health Sciences

First Advisor

Amanda Seymour MS, PA-C

Abstract

Patients with stages III-V CKD have increased risk for cardiovascular mortality due the correlation between the renal and cardiovascular systems, partially due to hyperphosphatemia. By controlling elevated phosphate levels the risk for cardiovascular damage is reduced. This is typically managed using phosphate binders and dietary phosphate restrictions. The intention of this review is to analyze non-calcium phosphate binders efficacy in reducing serum phosphate levels therefore mitigating risk for cardiovascular comorbidities when compared to calcium-based phosphate binders in patients with III-IV CKD.

Additional Files

Reference Full Capstone.docx (16 kB)
Poster Presentation.pdf (2264 kB)

Share

COinS
 

Efficacy of non-calcium phosphate binders compared to calcium phosphate binders in the treatment of hyperphosphatemia in stage III-V CKD

Patients with stages III-V CKD have increased risk for cardiovascular mortality due the correlation between the renal and cardiovascular systems, partially due to hyperphosphatemia. By controlling elevated phosphate levels the risk for cardiovascular damage is reduced. This is typically managed using phosphate binders and dietary phosphate restrictions. The intention of this review is to analyze non-calcium phosphate binders efficacy in reducing serum phosphate levels therefore mitigating risk for cardiovascular comorbidities when compared to calcium-based phosphate binders in patients with III-IV CKD.